The Food and Drug Administration today authorized Innovative Health Solutions Inc. to market an electrical nerve stimulator device to relieve opioid withdrawal symptoms when placed behind the patient’s ear. Previously approved for use in acupuncture, the NSS-2 Bridge device reduced symptoms for patients undergoing opioid withdrawal during a clinical study by at least 31% within 30 minutes, based on the clinical opiate withdrawal scale. Sixty-four of the 73 patients in the study transitioned to medication assisted therapy after five days using the device. “The FDA is committed to supporting the development of novel treatments, both drugs and devices, that can be used to address opioid dependence or addiction, as well as new, non-addictive treatments for pain that can serve as alternatives to opioids,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Blog
During National Nurses Week, Robyn Begley, AHA Senior Vice President and Chief Nursing Officer and CEO of AHA’s American Organization of Nurse Executives,…
Blog
In this AHA Stat blog post, Elisa Arespacochaga, vice president of the AHA Physician Alliance, highlights strategies from four female physicians who…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Headline
During National Nurses Week, which kicks off today, AHA and its American Organization of Nurse Executives subsidiary celebrate nurses for the invaluable role…